Patricio Massera was appointed Chief Executive Officer of AGC Biologics (formerly CMC Biologics) in May 2019. Patricio joined the company in 2012, as General Manager of Copenhagen-based CMC Biologics A/S. He later served as Chief Operating Officer in the Seattle-based company headquarters. As CEO, Patricio quickly developed a comprehensive people management strategy, recognizing that with a healthy company culture and highly engaged employees, AGC is best positioned to provide the highest-quality services to our customers. Across his 20 years of biologics experience, Patricio held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó and other biotech companies in Spain, Brazil, and Argentina. With a background in biochemistry and business, Patricio has acted as a change agent in several integration processes and cultivated strong leadership teams, dedicated to developing, manufacturing, and controlling biotechnological products and vaccines for human and animal health.
Patricio holds an MBA from UCEMA and a Biochemist degree from the University of Buenos Aires.
Vijay Raghavan became the Chief Financial Officer for AGC Biologics in January 2020. Vijay joined the company as Senior Vice President of Global Finance in April 2018, and has been a dedicated member and leader of the team, driving organizational growth through strategic financial planning, treasury, reporting and accounting. As CFO, Vijay continues to build value for the company, ensuring that AGC Biologics optimizes resource use to support the health and growth of our company and our customers. Vijay joined AGC Biologics after several years working in finance leadership roles at Cray and Microsoft. He leverages his 25 years of progressive experience in accounting, finance, business partnerships, strategic planning, and reporting for companies ranging from startups to conglomerates.
Outside of work, Vijay is dedicated to community service, including leadership positions at Hopelink and the Indian Association of Western Washington. Vijay earned a Masters of Commerce, Accounting, and Banking from the University of Madras in India, and an M.B.A. from the University of Hartford.
Kasper Møller was appointed to the role of Chief Technical Officer in June 2019, after serving for two years as General Manager and Site Head for our Copenhagen facility. Throughout his 14 years at AGC Biologics, Kasper has provided expertise in process characterization and validation, in previous roles such as Principal Scientist, Department Manager within Process Development, Vice President of Process Development and Vice President of Manufacturing. Earlier in his career, Kasper spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research, and teaching fermentation technology and metabolic engineering.
Kasper earned a Ph.D. in Biochemical Engineering, with a focus on microbial physiology, from the Technical University of Denmark. He pursued his post-doc at the university’s Center for Process Biotechnology, as well as the Department of Genetics at Washington University Medical School in St. Louis. Along the way, he contributed to more than a dozen scientific international journals and publications.
Mark joined AGC Biologics in February 2018, as Senior Vice President of Integration Management and Business Excellence. He brings 25 years as a management consulting industry leader and C-level client advisor. After principal positions at Capgemini and Celerant, Mark founded his own boutique consultancy, J.W. Webb Inc., and guided many of the world's renowned companies to achieve record highs in revenue and profit, leaving behind a Fortune 500 list of stronger leaders. He began his professional journey in the military, leading a succession of U.S. Navy units to unprecedented results.
Mark holds an Executive Management Certification from Harvard Business School, a Master of Science in Organizational Development from Chapman University, and a Bachelor of Science in Education from Southern Illinois University.
Daisy Szabo, Global Vice President of Human Resources, joined AGC Biologics in April 2017, and is responsible for strategic business alignment, process improvement for restructuring and growth, talent acquisition, change management, and operational excellence. Daisy brings more than 18 years of strategic experience, across industries including financial services, high-tech, and power generation, in environments ranging from startups to Fortune 100 companies, across Asia and the Americas. Daisy takes a cross-cultural approach to cultivating a workforce, having owned her own company in the apparel industry import distribution.
Daisy is dedicated to community service. She sits on the board of the STEM program for University of Washington Bothell, and is a board member for Open Doors USA. Daisy earned a Diplôme d' Études Collegiales from Marianopolis College (CEGEP) in Montreal, a Bachelor’s of Commerce from McGill University, and a Master of Business Administration from Azusa Pacific University.
As Senior Vice President, Global Quality, Paul Tsang is responsible for the advanced systems and processes of AGC Biologics around the world. Having joined AGC Biologics in 2015, as Vice President for the Quality Department, he directed the successful integration of quality management systems across three companies, including the development of a quality manual, global policies, and an electronic OMS. Paul brings more than 25 years of experience in the development of protein and small-molecule products. Prior to joining AGC Biologics, he held positions of increasing responsibility at Amgen and Eli Lilly in operations, quality, and analytics. Paul is constantly seeking new approaches to advance our rigorous standards.
Paul is involved in our community and industry. He is the life sciences sector representative on the Business & Philanthropy Leadership Committee for Career Connect Washington. He earned a Ph.D. in Chemistry from Texas A&M University and a Bachelor of Science in Applied Chemistry from Harvey Mudd College.
SoYoung Kwon, Vice President, General Counsel & Corporate Secretary, oversees all legal matters, including licensing, research and development, compliance, human resources, and transactions. SoYoung joined AGC Biologics in 2015, as Vice President of Legal Affairs. With more than 20 years of experience, she shapes legal strategy to manage risk and drive our mission. She serves as primary counsel to the ACG Biologics board of directors and all its committees.
SoYoung holds a Juris Doctorate from Willamette University College of Law, and completed the Asian and Comparative Law LL.M. (Master of Law) program at the University of Washington. Beyond the office, SoYoung dedicates herself to community involvement. For many years, she served on the Board of Directors of the Seattle Symphony Orchestra. She currently serves on the Seattle Art Museum Education and Community Engagement Committee, and is president of the Washington Scholarship Foundation.
Hiroshi Nishimura was appointed Senior Vice President, Corporate and Strategic Planning, in January 2020 after 33 years with AGC Inc. Prior to his recent appointment, Hiroshi served as Chief Financial Officer of AGC Biologics operations at the Seattle-based company headquarters for two years. Since joining Asahi Glass Company (now AGC Inc.), he has been engaged in a variety of assignments, including purchasing, sales of architectural glass, and corporate planning. In the late 90’s, Hiroshi pivoted toward sales operations in the U.S., with a focus on glass products imported from Japan. In 2016, Hiroshi joined our Life Science team as a leader of Planning and Accounting Management. With a focus on driving strategic business initiatives and fostering relationships with AGC headquarters, Hiroshi remains a vital part of the organization.
Hiroshi began his career by earning a bachelor’s degree in law from Tokyo University.
Chris Holt, General Manager and Site Head of our Seattle facility, delivers results through enabling his operational team and working closely with internal and external customers. Chris joined AGC Biologics in 2019, bringing his expertise in leading large teams in complex environments. Chris has more than 25 years of experience in the development and manufacturing of protein and small-molecule products. Along the way, Chris has stabilized his teams via employee engagement and an emphasis on nurturing talent and teamwork. As a result organizations under his leadership have developed and delivered sustainable improvements in quality, safety, delivery, capacity and cost. Chris honed his expertise in previous roles at Lonza, DSM/Patheon, and GlaxoSmithKline in the US and Europe, in engineering and manufacturing roles of increasing responsibility. From the shop floor to the C-suite, Chris assimilates the details and tackles implementation barriers in order to drive successful outcomes.
Chris holds a Bachelor of Science in Chemistry from the University of Nottingham and a Masters in Energy Engineering (Mechanical Services) from South Bank University in London.
J.D. Mowery, General Manager and Site Head of the Copenhagen facility, is an industry veteran with extensive global experience who has supported more than 25 commercial launches for biologics, cell therapies, generics, and biosimilars. J.D. joined AGC Biologics in 2019, bringing 20 years of experience in small molecule, biologics, and cell/gene therapy production environments as well as API synthesis and fine chemicals. He oversaw operations for multiple dosage types and therapeutic areas, including sterile injectables, ophthalmic and otic products, cell & gene therapies, and medical devices. Prior to AGC Biologics, J.D. worked for other industry leaders such as Celgene (Juno Therapeutics), Lonza, Genentech and Daiichi Sankyo. He was also a critical leader in the design, modification, and construction of eight commercial GMP facilities.
J.D. earned a Bachelor of Science in Project Management from George Fox University, and a Master of Business Administration at Marylhurst University, both in Oregon. He is a subject matter expert in aseptic processing, cell therapy and viral vector manufacturing. J.D. takes pride in his multiple awards for developing and investing in his people and teams, and continues to foster similar relationships with AGC in Copenhagen.
As the General Manager and Site Head of the Heidelberg facility, Dieter Kramer applies two decades of technical and leadership expertise. Dieter joined AGC Biologics in July 2018, having worked in a similar role at Corden Biochem GmbH, a full-service Contract Manufacturing Organization. Dieter brings breadth and depth to his role. Combining the disciplines of business and chemical engineering, he held various positions in R&D, manufacturing, project management and general management in the Sandoz/Novartis network in Austria and Germany. In particular, he spent five years as Managing Director of an API manufacturing site with large-scale fermentation and downstream capabilities.
Dieter pursued his education in Austria. He earned a Master of Business Administration from Management Center Innsbruck. He received his master’s degree in Technical Chemistry and Biotechnology at the Technical University of Graz. He completed his education at Höhere Technische Bundeslehranstalt in Wels with advanced study in chemical engineering.
As General Manager and Site Head, Naofumi Kagami oversees our multipurpose, highly efficient facility in Chiba, Japan. Naofumi joined AGC Biologics in 2019, and brings 25 years of industry experience. He worked previously for Roche Diagnostics, Lonza, and Sartorius Stedim in Japan, executing R&D, marketing, and sales roles of increasing leadership responsibility, for the life sciences and bio-manufacturing markets. Naofumi is also the owner of Castle104, Inc., an information resource that compiles and categorizes online research in the life sciences. In addition, Naofumi serves as vice chairman of the Minami-ikuta Elementary School PTA, and volunteers as an English assistant at Minami-ikuta Elementary School.
Naofumi earned a Bachelor of Science degree in Biochemistry and Biophysics from the University of Tokyo, and continued at the institution to complete his Master of Science.